AstraZeneca's Lung-Cancer Treatment Gets Recommended for Approval in the EU
15 Septiembre 2023 - 9:51AM
Noticias Dow Jones
By Christian Moess Laursen
AstraZeneca said its lung-cancer drug Enhertu has been
recommended for approval in the European Union following positive
test results.
The Anglo-Swedish pharma giant said Friday that Enhertu showed
an objective response rate of 49.0% and a median duration of
response of 16.8 months. In addition, the tests showed a disease
control rate of 93.1%.
The drug has been recommended for approval as a monotherapy for
the treatment of adult patients with advanced non-small-cell lung
cancer whose tumors have an activating HER2 mutation.
This form of lung cancer is an aggressive type that often
affects younger patients and has a poor prognosis, with limited
approved therapies.
"This milestone recognizes the unmet need in the EU and if
approved, Enhertu will provide the first targeted treatment option
for these patients," Executive Vice President Susan Galbraith
said.
Enhertu is being jointly developed and commercialized with
Japan's Daiichi Sankyo.
Write to Christian Moess Laursen at christian.moess@wsj.com
(END) Dow Jones Newswires
September 15, 2023 10:36 ET (14:36 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Daiichi Sankyo (PK) (USOTC:DSNKY)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Daiichi Sankyo (PK) (USOTC:DSNKY)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Daiichi Sankyo Company Ltd (PK) (OTCMarkets): 0 recent articles
Más de Daiichi Sankyo Company Ltd (PK) Artículos de Noticias